Intimation of Schedule of Analyst / Institutional Investor Meetings

August 7, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex, Bandra (East), Mumbai P.J. Towers, Dalal Street, – 400 051 Mumbai – 400 001 Scrip Name: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 43/26-27 Our Reference No. 43/26-27 Dear Sir, Sub: Intimation of Schedule of Analyst / Institutional Investor Meetings Pursuant to the relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform details of the Analyst / Institutional Investor meetings to be conducted as under: Group / Analyst/Institutional Type of Date Venue One-on- Investors/Event Meeting 12-08-2026 Emkay Confluence 2026 Mumbai Physical Both 17-08-2026 Motilal Oswal 22nd Annual Investor Mumbai Physical Both Conference 2026 01-09-2026 Elara India Dialogue 2026 Mumbai Physical Both 17-09-2026 Kotak Healthcare Forum Mumbai Physical Both The company will not be disclosing any Unpublished Price Sensitive Information (UPSI) at these meetings. The schedule of the above-mentioned meetings is subject to change due to exigencies on the part of Investor / Company. We request you to take this intimation on record. Thanking you. Yours faithfully, For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS – 28839 Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com